

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2010

(Rs.in Lakhs)

	Particulars	STANDALONE					CONSOLIDATED				
		Quarter ended		Nine Months ended		Year ended	Quarter ended		Nine Months ended		Year ended
		31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010	31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	31005	18990	82589	61554	92928	30969	19631	82850	62748	94161
	(b) Other Operating Income	385	594	1016	1898	1737	351	768	840	2147	2232
	<u>Total Income</u>	31390	19584	83605	63452	94665	31320	20399	83690	64895	96393
2	<u>Expenditure:</u>										
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	1105	(3455)	558	(8311)	(9924)	797	(3075)	42	(7732)	(9339)
	b. Consumption of Raw Material	10741	8478	31774	28001	39521	10853	8538	31868	28136	39658
	c. Purchase of Traded Goods	0	0	0	0	0	0	0	0	0	0
	d. Staff Cost	1974	1635	5573	5076	6846	2107	1758	5956	5441	7334
	e. Depreciation	1352	1326	3990	3917	5145	1353	1326	3993	3919	5148
	f. Other Expenditure										
	- Manufacturing Expenses	2669	1907	7311	5322	7174	2810	2045	7647	5590	7456
	- Other expenses	2552	2076	6923	5617	8126	2706	2172	7321	5920	8527
	g. Total	20393	11967	56129	39622	56888	20626	12764	56827	41274	58784
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	10997	7617	27476	23830	37777	10694	7635	26863	23621	37609
4	Other Income	708	380	1794	979	1333	673	255	1694	854	1202
5	Profit before Interest & Exceptional Items (3+4)	11705	7997	29270	24809	39110	11367	7890	28557	24475	38811

6	Finance Charges	56	177	163	560	276	55	177	163	562	278
7	Profit after Interest but before Exceptional Items (5-6)	11649	7820	29107	24249	38834	11312	7713	28394	23913	38533
8	Exceptional items	0	0	0	0	0	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax</u> (7+8)	11649	7820	29107	24249	38834	11312	7713	28394	23913	38533
10	Tax Expense										
	- Current Tax	1190	1035	2600	2735	3120	1190	1035	2600	2735	3120
	- MAT Credit Entitlements	111	0	184	0	960	111	0	184	0	960
	- Deferred Tax	191	(94)	241	95	334	169	(106)	202	82	419
11	<u>Net Profit from ordinary activities after Tax:</u> (9-10)	10157	6879	26082	21419	34420	9842	6784	25408	21096	34034
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	10157	6879	26082	21419	34420	9842	6784	25408	21096	34034
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	2651	2615	2651	2615	2643	2651	2615	2651	2615	2643
15	Reserves excluding revaluation reserves					151565					149138
16	Earnings per Share										
a)	Basic Earnings Per Share before extra-ordinary items Rs.	7.68	5.28	19.71	16.44	26.40	7.44	5.21	19.20	16.19	26.11
	Diluted Earnings Per Share before extra-ordinary items Rs.	7.67	5.25	19.70	16.33	26.35	7.43	5.17	19.19	16.09	26.06
b)	Basic Earnings Per Share after extra-ordinary items Rs.	7.68	5.28	19.71	16.44	26.40	7.44	5.21	19.20	16.19	26.11
	Diluted Earnings Per Share after extra-ordinary items Rs.	7.67	5.25	19.70	16.33	26.35	7.43	5.17	19.19	16.09	26.06
17	Public shareholding:										
	- No. of shares	63380320	61575945	63380320	61575945	62948545	63380320	61575945	63380320	61575945	62948545
	- % of shareholding	47.81%	47.10%	47.81%	47.10%	47.64%	47.81%	47.10%	47.81%	47.10%	47.64%
18	Promoters and promoter group shareholding:										
	a) pledged / encumbered	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	b) non-encumbered:										
	No. of shares	69185100	69168600	69185100	69168600	69195600	69185100	69168600	69185100	69168600	69195600

	Percentage of shares (as a % of the total shareholding of the promoter group)	100%	100%	100%	100%	100%		100%	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	52.19%	52.90%	52.19%	52.90%	52.36%		52.19%	52.90%	52.19%	52.90%	52.36%

NOTES:

1. The above results for the period ended 31st December 2010, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 4th February, 2011 and were subjected to "limited review" by the Auditors.
2. The consolidated results include the unaudited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG
3. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting notified under the Companies Act, 1956.
4. Exceptional item of Rs.5404 lakhs provided during the 1st quarter of last year towards tax liability of earlier years has been withdrawn as the relevant tax provisions have since been amended in Finance Act of 2010.
5. The company is implementing a project for setting up a new Unit called "DSN SEZ Unit" at Visakhapatnam at an estimated cost of Rs.200 crores.
6. During the current quarter, the company has allotted 34,180 equity shares of Rs.2/- each to the employees on exercise of their stock options.
7. The figures for the previous year/period have been reclassified/regrouped, wherever necessary.
8. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.12.2010:
Opening: Nil, Received during the Quarter: 12, Resolved: 12, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 04-02-2011

Dr. Murali K. Divi
Chairman & Managing Director